Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KDR2-2
- Development stage
- Phase 2
- Lead developer
- Guangzhou Huibairui Biomedical Technology
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
KDR2-2 is a novel small molecule tyrosine kinase inhibitor developed for ophthalmic use, specifically as an eye drop formulation. It acts primarily as a potent antagonist of vascular endothelial growth factor receptor 2 (VEGFR2), with moderate inhibitory activity against platelet-derived growth factor receptor beta (PDGFR-β). By inhibiting VEGFR2, KDR2-2 disrupts angiogenesis and neovascularization processes in the eye. Its main indications under investigation are corneal neovascularization and neovascular glaucoma. Clinical studies have evaluated its efficacy and safety in these conditions, showing anti-neovascular effects without significant side effects or complications in early trials[1][5][7].
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on KDR2-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KDR2-2.